Carboplatino

Resumen

Alternativas con registro en Colombia

• Cisplatino · costo anual estimado $ 358.795
• Oxaliplatino

Estudios clínicos principales

• COMBINATION: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors
  Fase 2 · 2022 · 5 participantes · Amsterdam UMC, location VUmc · NCT05298176
• CheckMate 227: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Double
  Fase 3 · 2015 · 2.747 participantes · Bristol-Myers Squibb · NCT02477826
• Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
  Fase 3 · 2010 · 1.516 participantes · ECOG-ACRIN Cancer Research Group · NCT01107626 · PubMed 31361535
• FLAURA2: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (
  Fase 3 · 2019 · 587 participantes · AstraZeneca · NCT04035486

Enfermedades relacionadas

• Cáncer (todos)
• Cáncer de mama
• Cáncer de vejiga y urotelial
• Cáncer de ovario
• Cáncer de cabeza y cuello

Fuentes

• Etiqueta FDA (DailyMed): CARBOPLATIN
• Resolución INVIMA 2024007014